KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the long-term efficacy and safety of different
dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects
with non-dialysis dependent chronic kidney disease (CKD).